Terazosin
Alpha-Adrenoreceptor Antagonists
- Drug class
- Alpha-Adrenoreceptor Antagonists
- Availability
- Prescription only
- Routes
- Oral
- Markets covered
- 3
- Products on record
- 27
- FDA reports (12 mo)
- 276
Overview
Plain-language summary, compiled from the cited regulatory records
Terazosin is an active ingredient classified as an Alpha-Adrenoreceptor Antagonist [1]. It is approved for the treatment of symptomatic benign prostatic hyperplasia (BPH) [1]. Clinical studies indicate that terazosin capsules lead to a rapid response in many patients, with approximately 70% experiencing improved urinary flow and symptom relief associated with BPH [1]. The long-term impact of terazosin capsules on the need for surgery, acute urinary obstruction, or other BPH complications is still under evaluation [1].
In the past 12 months, there have been 276 adverse event reports associated with terazosin [2]. The most frequently reported events include fatigue, off-label use, death, diarrhea, and the drug being ineffective [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| CA Canada | Health Canada | 16 | November 5, 2025 |
| GB United Kingdom | MHRA | 8 | May 15, 2026 |
| US United States | FDA | 3 | December 20, 2024 |
CACanada· Health Canada
16 products
Uses
AND CLINICAL USE ............................................................................. 3 CONTRAINDICATIONS ................................................................................................... 4 WARNINGS AND PRECAUTIONS .................................................................................
4 ADVERSE REACTIONS ................................................................................................... 9 DRUG INTERACTIONS .................................................................................................
12 DOSAGE AND ADMINISTRATION ............................................................................. 13 OVERDOSAGE ................................................................................................................
15 ACTION AND CLINICAL PHARMACOLOGY ............................................................ 15 STORAGE AND STABILITY ......................................................................................... 17 DOSAGE FORMS, COMPOSITION AND PACKAGING.............................................
GBUnited Kingdom· MHRA
8 products
Uses
Terazosin tablets are indicated for: • The treatment of mild to moderate hypertension • The symptomatic treatment of urinary obstruction caused by benign prostatic hyperplasia (BPH).
How to take
USUnited States· FDA
3 products
Uses
INDICATIONS AND USAGE
Terazosin capsules are indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH). There is a rapid response, with approximately 70% of patients experiencing an increase in urinary flow and improvement in symptoms of BPH when treated with terazosin capsules.
The long-term effects of terazosin capsules on the incidence of surgery, acute urinary obstruction or other complications of BPH are yet to be determined. Terazosin capsules are also indicated for the treatment of hypertension. Terazosin capsules can be used alone or in combination with other antihypertensive agents such as diuretics or beta-adrenergic blocking agents.
How to take
Drug interactions
Known interactions involving Terazosin. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 367. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]Health Canada (DPD) · 02243518 · revised March 22, 2025
- [2]MHRA (UK) · PL200750093 · revised May 15, 2026
- [3]FDA DailyMed · 0574d9ae-04da-4c… · revised July 20, 2023 [PDF]
- [4]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.